New Approaches for Cryptococcosis Treatment

Identification of off-patent drugs that show synergism with Amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp.

(2020) Suélen Andreia Rossi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

(2019) Grace Cuddihy et al.   Pharmaceutics

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

(2019) Miao Zhao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tetrazole hybrids and their antifungal activities

(2019) Sheng-Qiang Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis

(2019) R. Lu et al.   mBio

In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017

(2019) M. A. Pfaller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis

(2019) Cristina de Castro Spadari et al.   International Journal of Nanomedicine

The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans

(2019) Trieu Phan Hai et al.   MYCOSES

Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial

(2019) Joshua Rhein et al.   LANCET INFECTIOUS DISEASES

Borneol and poly (ethylene glycol) dual modified BSA nanoparticles as an itraconazole vehicle for brain targeting

(2019) Shanshan Zhang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Miltefosine has post-antifungal effect and induces apoptosis in Cryptococcus yeasts

(2018) Cristina de Castro Spadari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro and in vivo Evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus

(2018) Karen Joy Shaw et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease

(2018) Gemma L. Nixon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity

(2018) Anran Qian et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The antifungal arsenal: alternative drugs and future targets

(2018) Nathan P. Wiederhold   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis

(2018) E P Garvey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Crossing the blood-brain barrier with nanoparticles

(2018) Yiqun Zhou et al.   JOURNAL OF CONTROLLED RELEASE

Aspergillus terreus: Novel lessons learned on amphotericin B resistance

(2018) Wilfried Posch et al.   MEDICAL MYCOLOGY

A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species

(2018) Felix Bongomin et al.   MYCOSES

Repurposing drugs to fast-track therapeutic agents for the treatment of cryptococcosis

(2018) Megan Truong et al.   PeerJ

Future perspectives for cryptococcosis treatment

(2018) Juliana Santos-Gandelman et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries

(2018) Angela Loyse et al.   LANCET INFECTIOUS DISEASES

Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances

(2018) Xiaoqian Niu et al.   Asian Journal of Pharmaceutical Sciences

Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles

(2017) Anamarija Ćurić et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

(2017) Romuald Bellmann et al.   INFECTION

In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen

(2017) Hiroshi Nishikawa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus

(2017) Nathan P Wiederhold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fungal infections in HIV/AIDS

(2017) Andrew H Limper et al.   LANCET INFECTIOUS DISEASES

Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

(2017) Radha Rajasingham et al.   LANCET INFECTIOUS DISEASES

Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole

(2017) Rui Kano et al.   MEDICAL MYCOLOGY

Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis

(2017) Fernanda Wirth et al.   MEDICAL MYCOLOGY

The antifungal pipeline: a reality check

(2017) John R. Perfect   NATURE REVIEWS DRUG DISCOVERY

Repurposing itraconazole as an anticancer agent

(2017) Hiroshi Tsubamoto et al.   Oncology Letters

The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans

(2017) Luna S. Joffe et al.   Frontiers in Microbiology

The celecoxib derivative AR-12 has broad spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis

(2016) Kristy Koselny et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates PotentIn VitroActivity against Cryptococcus neoformans and Cryptococcus gattii

(2016) Shawn R. Lockhart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cryptococcosis

(2016) Eileen K. Maziarz et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex

(2016) Rossana de Aguiar Cordeiro et al.   MICROBIOLOGY-SGM

Molecular identification, antifungal resistance and virulence ofCryptococcus neoformansandCryptococcus deneoformansisolated in Seville, Spain

(2016) Sara Gago et al.   MYCOSES

Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase

(2016) Kristy Koselny et al.   ACS Infectious Diseases

Development and lyophilization of itraconazole loaded poly(butylcyanoacrylate) nanospheres as a drug delivery system

(2015) Anamarija Ćurić et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Cryptococcosis diagnosis and treatment: What do we know now

(2015) John R. Perfect et al.   FUNGAL GENETICS AND BIOLOGY

Activity of sertraline againstCryptococcus neoformans:in vitroandin vivoassays

(2015) Rogelio de J. Treviño-Rangel et al.   MEDICAL MYCOLOGY

Cryptococcus: from environmental saprophyte to global pathogen

(2015) Robin C. May et al.   NATURE REVIEWS MICROBIOLOGY

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids

(2015) Visesato Mor et al.   mBio

Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges

(2014) Meeta Gidwani et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

An update on pharmacotherapy for leishmaniasis

(2014) Shyam Sundar et al.   EXPERT OPINION ON PHARMACOTHERAPY

A Case of Fluconazole, Voriconazole-ResistantCryptococcus neoformansIsolated from an Immunocompetent Patient

(2014) N. Mandras et al.   JOURNAL OF CHEMOTHERAPY

Estrogen Receptor Antagonists Are Anti-Cryptococcal Agents That Directly Bind EF Hand Proteins and Synergize with Fluconazole In Vivo

(2014) A. Butts et al.   mBio

Synthesis and antifungal activities of miltefosine analogs

(2013) Ranga Rao Ravu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

C2′-OH of Amphotericin B Plays an Important Role in Binding the Primary Sterol of Human Cells but Not Yeast Cells

(2013) Brandon C. Wilcock et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries

(2013) Angela Loyse et al.   LANCET INFECTIOUS DISEASES

Nanoparticulate systems for brain delivery of drugs

(2012) Jörg Kreuter   ADVANCED DRUG DELIVERY REVIEWS

Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis

(2012) Joseph N. Jarvis et al.   AIDS

Limited Activity of Miltefosine in Murine Models of Cryptococcal Meningoencephalitis and Disseminated Cryptococcosis

(2012) N. P. Wiederhold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast

(2012) Tatsuya Shibata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections

(2012) Bing Zhai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection

(2012) Kun Shao et al.   BIOMATERIALS

The Cryptococcus neoformans Capsule: a Sword and a Shield

(2012) T. R. O'Meara et al.   CLINICAL MICROBIOLOGY REVIEWS

Fluconazole resistance in cryptococcal disease: emerging or intrinsic?

(2012) Jenny Wan Sai Cheong et al.   MEDICAL MYCOLOGY

Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment

(2011) Michael A. Pfaller   AMERICAN JOURNAL OF MEDICINE

Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice

(2011) Xu et al.   International Journal of Nanomedicine

Transport of drugs across the blood–brain barrier by nanoparticles

(2011) Stefanie Wohlfart et al.   JOURNAL OF CONTROLLED RELEASE

Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole

(2011) M. Spitzer et al.   Molecular Systems Biology

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain

(2010) Kun Shao et al.   JOURNAL OF CONTROLLED RELEASE

Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles

(2010) Wei Chen et al.   JOURNAL OF DRUG TARGETING

Vitamin E TPGS P-Glycoprotein Inhibition Mechanism: Influence on Conformational Flexibility, Intracellular ATP Levels, and Role of Time and Site of Access

(2010) Eva-Maria Collnot et al.   MOLECULAR PHARMACEUTICS

Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence

(2009) E. Sionov et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preparation and Therapeutic Efficacy of Polysorbate-80-Coated Amphotericin B/PLA-b-PEG Nanoparticles

(2009) Tianbin Ren et al.   JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION

Hydrogel nanoparticles in drug delivery

(2008) Mehrdad Hamidi et al.   ADVANCED DRUG DELIVERY REVIEWS

In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine

(2008) J. Mitsuyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY